|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Fluvoxamine results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance |
ISO |
ABCB1A protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
affects response to substance |
ISO |
ABCB1B protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:15502009 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Fluvoxamine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Avp |
arginine vasopressin |
increases expression |
ISO |
Fluvoxamine results in increased expression of AVP protein |
CTD |
PMID:11195401 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Fluvoxamine results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Fluvoxamine results in increased activity of CASP3 protein] |
CTD |
PMID:22700542 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity multiple interactions |
ISO |
Fluvoxamine results in increased activity of CASP7 protein Palmitic Acid promotes the reaction [Fluvoxamine results in increased activity of CASP7 protein] |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Fluvoxamine results in decreased activity of CYP19A1 protein |
CTD |
PMID:26162595 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity increases response to substance increases expression |
ISO EXP |
[Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Phenacetin; [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in increased chemical synthesis of Aconitine metabolite; CYP1A2 protein binds to and affects the metabolism of Fluvoxamine; Enoxacin inhibits the reaction [CYP1A2 protein affects the metabolism of Fluvoxamine]; Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of olanzapine]; Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of Theophylline]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of Acetaminophen]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of clozapine N-oxide]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of norclozapine]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin] CYP1A2 protein results in increased susceptibility to Fluvoxamine [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Caffeine fluvoxamine increases expression of CYP1A2 mRNA and protein in cervical cancer cells |
CTD RGD |
PMID:9029748 PMID:11763009 PMID:15545309 PMID:15845683 PMID:15905806 PMID:18809730 PMID:18816299 PMID:21277363 PMID:21915887 PMID:26599973 PMID:30979496 More...
|
RGD:401976472 |
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Fluvoxamine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of GAD1 protein |
CTD |
PMID:15967061 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
affects response to substance |
ISO |
HTR2A gene SNP affects the susceptibility to Fluvoxamine |
CTD |
PMID:12607287 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO EXP |
Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of ICAM1 mRNA] Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
[Terfenadine co-treated with Fluvoxamine] binds to and results in decreased activity of KCNH2 protein; Fluvoxamine binds to and results in decreased activity of KCNH2 protein; Fluvoxamine inhibits the reaction [KCNH2 protein results in increased transport of Thallium] Fluvoxamine results in decreased activity of KCNH2 protein |
CTD |
PMID:20071423 PMID:21158687 PMID:24052561 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP ISO |
Fluvoxamine results in increased expression of NOS2 mRNA Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA] Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA] |
CTD |
PMID:12429386 PMID:27803785 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of PRKCB protein |
CTD |
PMID:15967061 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP ISO |
Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA] Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
decreases activity affects response to substance |
ISO |
Fluvoxamine results in decreased activity of SCN5A protein SCN5A protein affects the susceptibility to Fluvoxamine |
CTD |
PMID:19875396 |
|
NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP ISO |
Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA] Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of VCAM1 mRNA] |
CTD |
PMID:27803785 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|